Immune Dysfunction and the Pathogenesis of AIDS-associated non-Hodgkin's Lymphoma

Memorias do Instituto Oswaldo Cruz

Volumn 93, Issue 3, 1998, Pages 373-381

  Martínez Maza, Otoniel ^a   Widney, Daniel ^a   Van Der Meijden, Meta ^a   Knox, Reba ^a   Echeverri, Angela ^a   Breen, Elizabeth C ^a   Magpantay, Larry ^a   Miles, Steven A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; B lymphocytes; HHV8; HIV; Interleukin 6; Lymphoma

Indexed keywords

CYTOKINE; INTERLEUKIN 6 RECEPTOR;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL DIVISION; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOLOGY; NONHODGKIN LYMPHOMA; PATHOGENICITY; PATHOLOGY;

B-LYMPHOCYTES; CELL DIVISION; CYTOKINES; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; RECEPTORS, INTERLEUKIN-6;

EID: 0032067324     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02761998000300019     Document Type: Article

References (91)

1. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK 1993. CD40 expression by human monocytes: regulation by cytokines and activation by the ligand for CD40. J Exp Med 178: 669-674.
2. Amadori A, Zamarchi R, Ciminale V, Del Mistro A, Siervo S, Alberti A, Colombatti M, Chieco-Bianchi L 1989. HIV-1-specific B-cell activation: a major constitutent of spontaneous B cell activation during HIV-1 infection. J Immunol 143: 2146-2152.
3. Amadori A, Zamarchi R, Veronese ML, Panozzo M, Barelli A, Borri A, Sironi M, Colotta F, Mantovani A, Chieco-Bianchi L 1991. B cell activation during HIV-1 infection. II. Cell-to-cell interactions and cytokine requirement. J Immunol 146: 57-62.
4. Armitage RJ, Tough TW, Macduff BM, Fanslow WC, Spriggs MK, Ramsdell F, Alderson MR 1993. CD40 ligand is a T cell growth factor. Eur J Immunol 23: 2326-2331.
5. Ballerini P, Gaidano G, Gong JZ, Tassi V, Saglio G, Knowles DM, Dalla-Favera R 1993. Multiple genetic lesons in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 81: 166-176.
6. Beral V, Peterman T, Berkelman R, Jaffe H 1991. AIDS non-Hodgkin lymphoma. Lancet 337: 805-809.
7. Berberian L, Goodglick L, Kipps TJ, Braun J 1993. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 261: 1588-1591.
8. Berberian L, Valles-Ayoub Y, Sun N, Martinez-Maza O, Braun J 1991. A VH clonal deficit in HIV-positive individuals reflects a B cell maturational arrest. Blood 78: 175-179.
9. Birx DL, Redfield RR, Tosato G 1986. Defective regulation of EBV infection in patients with Acquired Immunodeficiency Syndrome (AIDS) or AIDS-related disorders. New Engl J Med 314: 874-879.
10. Birx DL, Redfield RR, Tencer K, Fowler A, Burke DS, Tosato G 1990. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 76: 2303-2310.
11. Blackbourn DJ, Amroziak J, Lennette E, Adams M, Ramachandran B, Levy JA 1997. Infectious human herpesvirus 8 in a healthy North American blood donor. Lancet 349: 609-611.
12. Breen EC, Rezai AR, Nakajima K, Beau GN, Mitsuyasu RT, Hirano T, Kishimoto T, Martinez-Maza O 1990. Infection with HIV is associated with elevated IL6 levels and production. J Immunol 144: 480-484.
13. Burdin N, Rousset F, Banchereau J 1997. B-cell-derived IL-10: production and function. Methods 11: 98-111.
14. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. New Eng J Med 332: 1186-1191.
15. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865-1869.
16. Chirmule N, Kalyanaraman VS, Lederman S, Oyaizu N, Yagura H, Yellin MJ, Chess L, Pahwa S 1993. HIV-gp160-induced T cell-dependent B cell differentiation. Role of T cell-B cell activation molecule and IL6. J Immunol 150: 2478-2486.
17. Clouse KA, Cosentino LM, Weih KA, Pyle SW, Robbins PB, Hochstein HD, Natarajan V, Farrar WL 1991. HIV gp120 env protein has the intrinsic capacity to stimulate monokine secretion. J Immunol 147:2892-2901.
18. de Wit R, Raasveld MH, ten Berge RJ, van der Wouw PA, Bakker PJ, Veenhof CH 1991. Interleukin-6 concentrations in the serum of patients with AIDS-associated Kaposi's sarcoma during treatment with interferon-alpha. J Internal Med 229: 539-542.
19. Del Prete G, Maggi E, Pizzolo G, Romagnani S 1995. CD30, TH2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 16: 76-80.
20. Edelman AS, Zolla-Pasner S 1989. AIDS: a syndrome of immune dysregulation, dysfunction, and deficiency. FASEB J 3: 22-30.
21. Emilie D, Coumbaras J, Raphael M, Devergne O, Delecluse HJ, Gisselbrecht C, Michiels JF, Van Damme J, Taga T, Kishimoto T, Crevon MC, Galanaud P 1992. IL-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood 80: 498-504.
22. Emilie D, Touitou R, Raphael M, Peuchmaur M, Devergnee O, Rea D, Coumbraras J, Crevon M-C, Edelman L, Job I, Galanaud P 1992b. In vivo production of interleukin-10 by malignant cells in AIDS lymphoma. Eur J Immunol 22: 2937-2942.
23. Emilie D, Zou W, Fior R, Llorente L, Durandy A, Crevon MC, Maillot MC, Durand-Gasselin I, Raphael M, Peuchmaur M, Galamaud P 1997. Production and IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity. Methods 11: 133-142.
24. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921-924.
25. Erard F, Wild MT, Garcia-Sanz JA, Le Gros G 1993. Switch of CD8 T cells to noncytolytic CD8-CD4-cells that make TH2 cytokines and help B cells. Science 260: 1802-1805.
26. Gaidano G, Pastore C, Capello D, Migliazza A, Gloghini A, Saglio G, Carbone A, Dalla-Favera R 1997. Involvement of the bcl-6 gene in AIDS-related lymphomas. Ann Oncol 8: 105-108.
27. Gail MH, Pluda JM, Rabkin CS, Biggar RJ, Goedert JJ, Horm JW, Sondik EJ, Yarchoan R, Broder S 1991. Projections of the incidence of non-Hodgkin's lymphoma related to AIDS. J Natl Can Inst 83: 695-701.
28. Gearing DP, Comeau MR, Friend DJ, Gimple SD, Thut CJ, McGourty J, Brasher KK, King JA, Gillis S, Mosley B, Ziegler SF, Cosman D 1992. The IL6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255: 1434-1437.
29. Hirano T, Akira S, Kishimoto T 1990. Biological and clinical aspects of IL6. Immunol Today 11: 443-449.
30. Hirano T, Taga T, Yasukawa K, Nakajima K, Nakano N, Takatsuki F, Shimizu M, Murashima A, Tsunasawa S, Sakiyama F, Kishimoto T 1987. Human B cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. PNAS 84: 228-231.
31. Honda M, Kitamura K, Mizutani Y, Oishi M, Arai M, Okura T, Igarahi K, Yasukawa K, Hirano T, Kishimoto T 1991. Quantitative analysis of serum IL6 and its correlation with increased levels of serum IL2R in HIV-induced diseases. J Immunol 145: 4059-4064.
32. Karp JE, Broder S 1991. AIDS and non-Hodgkin's lymphomas. Cancer Res 51: 4743-4756.
33. Kishimoto T, Taga T, Akira S 1994. Cytokine signal transduction. Cell 76: 253-262.
34. Kishimoto T, Akira S, Narazaki M, Taga T 1995. Interleukin-6 family of cytokines and gp130. Blood 86: 1243-1254.
35. Klein G 1989. Multiple phenotypic consequences of the Ig/Myc translocation in B-cell-derived tumors. Genes Chromosomes Cancer 1: 3-8.
36. Knowles DM 1997. Molecular pathology of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Sem Diag Pathol 14: 67-82.
37. Knowles DM, Cesarman E 1997. The Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in Kaposi's sarcoma, malignant lymphoma, and other diseases. Ann Oncol 8: 123-129.
38. Lafeuillade I, Poizot-Martin R, Quilichini R, Gastaut JA, Kaplanski S, Farnarier C, Mege JL, Bongrand P 1991. Increased IL6 production is associated with disease progression in HIV infection. AIDS 5: 1139-1140.
39. Lane HC, Fauci AS 1985. Immunologic abnormalities in AIDS. Ann Rev Immunol 3: 477-500.
40. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci A 1983. Abnormalities of B-cell activation and immunoregulation in patients with AIDS. N Engl J Med 309: 453-458.
41. Lennette ET, Blackbourn DJ, Levy JA 1996. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 348: 858-861.
42. Liu M, Martinez-Maza O, Johnson MT, Fan J, Kishimoto T, Plaeger-Marshall S 1995. IL-6 induces target cell resistance to HIV-specific cytotoxic lysis. J AIDS Human Retrovirol 9: 321-331.
43. Lombardi L, Newcomb EW, Dalla-Favera R 1987. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV human B lymphoblasts. Cell 49: 161-170.
44. Macchia D, Almerigogna F, Parronchi P, Ravina A, Maggi E, Romagnani S 1993. Membrane tumor necrosis factor-alpha is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature 363: 464-466.
45. Macchia D, Parronchi P, Piccini MP, Simonelli C, Mazzetti M, Ravina A, Milo D, Maggi E, Romagnani S 1991. In vitro infection with HIV enables human CD4+ T cell clones to induce noncognate contact-dependent polyclonal B cell activation. J Immunol 145: 3413-3418.
46. Macgrath I 1992. Molecular basis of lymphomagenesis. Cancer Res 52: 5529s-5540s.
47. MacMahon EME, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC, Ambinder RF 1991. EBV in AIDS-related primary central nervous system lymphoma. Lancet 338: 969-973.
48. Marfaing-Koka A, Aubin JT, Grangeot-Keros L, Portier A, Benattar C, Merrien D, Agut H, Aucouturier P, Autran B, Wijdenes J 1996. In vivo role of IL-6 on the viral load and on immunological abnormalities of HIV-infected patients. J AIDS Human Retrovirol 11: 59-68.
49. Martinez-Maza O 1992. IL6 and AIDS. Res Immunol 143: 764-769.
50. Martínez-Maza O 1993. HIV-induced immune dysfunction and AIDS-associated neoplasms, p. 181-204. In MS Mitchell, Biological Approaches to Cancer Treatment - Biomodulation, McGraw-Hill, New York.
51. Martínez-Maza O, Crabb E, Mitsuyasu RT, Fahey JL, Giorgi JV 1987. Infection HIV is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol 138: 3720-3724.
52. Matsuda T, Suematsu S, Kawano M, Yoshizaki K, Tang B, Tanabe O, Nakajima T, Akira S, Hirano T, Kishimoto T 1989. IL6 in normal and abnormal regulation of immune responses. Ann NY Acad Sci 557: 466-476.
53. Minamoto S, Ikegame KL, Ueno K, Narazaki M, Naka T, Yamamoto H, Matsumoto T, Saito H, Hosoe S, Kishimoto T 1997. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Comm 237: 79-83.
54. Mizuma H, Litwin S, Zolla-Pazner S 1988. B cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunologic parameters. Clin Exp Immunol 71: 410-416.
55. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA 1997. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp 130 receptor subunit. J Biol Chem 272: 19625-19631.
56. Moore PS, Boshoff C, Weiss RA, Chang Y 1996. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274: 1739-1744.
57. Moore RD, Kessler H, Richman DD, Flexner C, Chaisson RE 1991. Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine. JAMA 265: 2208-2211.
58. Munoz A, Schrager LK, Bacellar H, Speizer I, Vermund SH, Detels R, Saah AJ, Kingsley LA, Seminara D, Phair JP 1993. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiology 137: 423-438.
59. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929.
60. 2) production by HIV. J Immunol 142: 531-536.
61. Neri A, Barriga F, Knowles DM, Magrath IT, Dalla-Favera R 1988. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt Iymphoma. PNAS (USA) 85: 2748-2752.
62. Nicholas J, Ruvolo V, Zong J, Ciufo D, Guo HG, Reitz MS, Hayward GS 1997. A single 13-kilobase divergent locus in the Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genome contains nine open reading frames that are homologous to or related to cellular proteins. J Virol 71: 1963-1974.
63. Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, Friedman-Kien AE, Fleckenstein B 1997. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 71: 839-842.
64. Noelle RJ, Ledbetter JA, Aruffo A 1992. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 13:431-433.
65. Paganelli R, Scala E, Ansotegui IJ, Ausiello CM, Halapi E, Fanales-Belasio E, D'Offizi G, Mezzaroma I, Pandolfi F, Fiorilli M 1995. CDS+ T lymphocytes provide helper activity for IgE synthesis in HIV-infected patients with hyper-IgE. J Exp Med 181: 423-428.
66. Pahwa S, Pahwa R, Saxinger C, Gallo RC, Good RA 1985. Influence of HTLV/LAV on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations. PNAS 82: 8198-8202.
67. Pahwa S, Pahwa R, Good RA, Gallo RC, Saxinger C 1986. Stimulatory and inhibitory influences of HIV on normal B lymphocytes. PNAS 83: 9124-9128.
68. Parker DC 1993. T cell-dependent B cell activation. Ann Rev Immunol 11: 331-360.
69. Pluda JM, Yarchoan R, Jaffe ES, Feuerstein IM, Solomon D, Steinberg SM, Wyvill KM, Raubitschek A, Katz D, Broder S 1990. Development of non-Hodgkin Lymphoma in a cohort of patients with severe HIV infection on long-term antiretroviral therapy. Ann Int Med 113: 276-282.
70. Potter M 1992. Pathogenetic mechanisms in B-cell non-Hodgkin's lymphomas. Cancer Res 52: 5522s-5528s.
71. Przybylski GK, Goldman J, Ng VL, McGrath MS, Herndier BG, Schenkein DP, Monroe JG, Silberstein LE 1996. Evidence for early B-cell activation preceding the development of Epstein-Barr virus-negative acquired immunodeficiency syndrome-related lymphoma. Blood 88: 4620-4629.
72. Rautonen J, Rautonen N, Martin NL, Philip R, Wara DW 1991. Serum IL6 concentrations are elevated and associated with elevated tumor necrosis factor-alpha and immunoglobulin G and A concentrations in children with HIV infection. AIDS 5: 1319-1325.
73. Rieckmann P, Poli G, Kehrl JH, Fauci AS 1991. Activated B lymphocytes from HIV-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1. J Exp Med 173: 1-5.
74. Rosenberg ZF, Fauci AS 1990. Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression, Immunol Today 11: 176-180.
75. Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ 1993. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 151: 2497-2510.
76. Russo JJ, Bohensky RA, Chien M-C, Chen J, Van M, Maddelena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). PNAS (USA) 93: 14862-14867.
77. Schnittman SM, Lane HC, Higgins SE, Folks T, Fauci AS 1986. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science 233: 1084-1086.
78. Schulz TF, Boshoff CH, Weiss RA 1996. HIV infection and neoplasia. Lancet 348: 587-591.
79. Seder RA, Le Gros CG 1995. The functional role of CDS+ T helper type 2 cells. J Exp Med 181: 5-7.
80. Shevach EM 1993. Accessory Modules, in Fundamental Immunology, 3rd ed., WE Paul, Raven Press, NY, 531 pp.
81. Shiramizu B, Macgrath I 1990. Localization of breakpoints by polymerase chain reactions in Burkitt's lymphoma with 8;14 translocations. Blood 75: 1848-1852.
82. Starr R, Wilson TA, Viney EM, Murray LJL, Rayner JR, Jenkins BJ, Gonda TJ, Alexander W, Metcalf D, Nicola NA, Hilton DJ 1997. A family of cytokine-inducible inhibitors of signaling. Nature 387: 917-921.
83. Subar M, Neri A, Inghirami G, Knowles DM, Dalla-Favera R 1988. Frequent c-myc oncogene activation and infrequent presence of EBV genome in AIDS-associated lymphoma. Blood 72: 667-671.
84. Takeshida S, Breen EC, Ivashchenko M, Rezai AR, Nishanian P, Vredevoe D, Kishimoto T, Martínez-Maza O 1995. Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein gp41 in the THP-1 human monocytic cell line. Cell Immunol 165: 234-242.
85. Tosato G, Blaese RM 1985. EBV infection and immunoregulation in man. Adv Immunol 37: 99-149.
86. Vincent C, Cozon G, Zittoun M, Mellquist M, Kazatchkine MD, Czerkinsky C, Revillard JP 1992. Secretory immunoglobulins in serum from HIV-infected patients. J Clin Immunol 12: 381-388.
87. Widney D, Yawetz S, van der Meyden M, Miles SA, Kishimoto T, Martínez-Maza O 1994. Effects of zidovudine on B lymphocyte activation. Cellular Immunol 158: 140-156.
88. Yarchoan R, Redfield RR, Broder S 1986. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. J Clin Invest 78: 439-447.
89. Yawetz S, Cumberland WG, van der Meyden M, Martinez-Maza O 1995. Elevated serum levels of soluble CD23 (sCD23) precede the appearance of AIDS-associated non-Hodgkin's lymphoma. Blood 85: 1843-1849.
90. Ziegler JL 1987. AIDS and cancer. Ann Inst Pasteur Immunol 138: 253-260.
91. Zinzani PL, Baccini C, Zaccaria A, Visani G, Buzzi M, Morelli A, Molinari AL, Salvucci M, Bendandi M, Rubboli D, Gherlinzoni F, Zanchini R, Tura S 1996. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma. Eur J Haematol 57: 335-340.